Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 1, 1999, Pages 50-58

  Liu, Ming ^a   Bryant, Matthew S ^a   Chen, Jianping ^a   Lee, Suining ^a   Yaremko, Bohdan ^a   Li, Zujun ^a   Dell, Janet ^a   Lipari, Phil ^a   Malkowski, Michael ^a   Prioli, Nicholas ^a   Rossman, Randall R ^a   Korfmacher, Walter A ^a   Nomeir, Amin A ^a   Lin, C C ^a   Mallams, Alan K ^a   Doll, Ronald J ^a   Catino, Joseph J ^a   Girijavallabhan, Viyyoor M ^a   Kirschmeier, Paul ^a   Bishop, W Robert ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Orally bioavailable; Ras; SCH 59228; Tricyclic farnesyl transferase inhibitor; Xenograft

Indexed keywords

[1 (3 BROMO 8 CHLORO 6,11 DIHYDRO 5H BENZO[5,6]CYCLOHEPTA[1,2 B]PYRIDIN 11 YL) 4 (4 PYRIDINYLACETYL)PIPERAZINE; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; SCH 59228; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; FIBROBLAST; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE; ONCOGENE RAS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; XENOGRAFT;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CELL DIVISION; CELL LINE, TRANSFORMED; COLONIC NEOPLASMS; CYCLIC N-OXIDES; ENZYME INHIBITORS; FIBROBLASTS; GENES, MOS; GENES, RAS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PIPERAZINES; TRANSFECTION;

EID: 0032914818     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050862     Document Type: Article

References (43)

1. 1. Barbacid M (1987) Ras genes. Annu Rev Biochem 56: 779
2. 2. Joneson T, White MA, Wigler MH, Bar-Sagi D (1996) Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS. Science 271: 810
3. 3. Moodie SA, Willumsen BM, Weber MJ, Wolfman A (1993) Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 260: 1658
4. 4. Lowy DR, Willumsen BM (1993) Function and regulation of Ras. Annu Rev Biochem 62: 851
5. 5. Leon J, Guerrero I, Pellicer A (1987) Differential expression of the ras gene family in mice. Mol Cell Biol 4: 1493
6. 6. Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49: 4682
7. 7. Gibbs JB, Oliff A, Kohl NE (1994) Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell 77: 175
8. 8. Gibbs JB, Kohl NE, Koblan KS, Omer CA, et al (1996) Farnesyltransferase inhibitors and anti-Ras therapy. Breast Cancer Res Treat 38: 75
9. 9. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T (1993) Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260: 85
10. 10. Plattner R, Anderson MJ, Sato KY, Fasching CL, et al (1996) Loss of oncogenic ras expression does not correlate with loss of tumorigenecity in human cells. Proc Natl Acad Sci USA 93: 6665
11. 11. Jackson JH, Cochrane CG, Bourne JR, Solski PA, et al (1990) Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc Natl Acad Sci USA 87: 3042
12. 12. Kato K, Cox AD, Hisaka MM, Graham SM, et al (1992) Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89: 6403
13. 13. Schaefer WR, Kim R, Sterne R, Thorner J, et al (1989) Genetic and pharmacological suppression of oncogenic mutations in RAS genes of yeast and humans. Science 245: 379
14. 14. James GL, Goldstein JL, Brown MS (1995) Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 270: 6221
15. 15. Zhang F, Bond R, Wang L, Windsor W, et al (1997) Characterization of H, K and N-Ras as in vitro substrates for isoprenyl protein transferases. J Biol Chem 272: 10232
16. 16. Whyte DB, Kirschmeir P, Hockenberry TN, Nunez-Oliva I, et al (1997) K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272: 14459
17. 17. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM (1997) Direct demonstration of geranylgeranylation and farnesylalion of Ki-Ras in vivo. J Biol Chem 272: 14093
18. 18. Bishop WR, Bond R, Petrin J, Wang L, et al (1995) Novel tricyclic inhibitors of farnesyl transferase. J Biol Chem 270: 30611
19. 19. Mallams AK, Rossman RR, Doll RJ, Girijavallabhan V, et al (1998) Inhibitors of farnesyl protein transferase. 4-amido, 4-carbamoyl and 4-carboxamido derivatives of 1-(8-chloro-6, 11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6] cyclohepta[1,2-b]pyridin-11-yl)piperazine. J Med Chem (in press)
20. 20. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor Press, Cold Spring Harbor
21. 21. Bryant MS, Korfmacher WA, Wang S, Nardo C, et al (1997) Pharmacokinetic screening for selection of new drug discovery candidates is greatly enhanced through the use of liquid chromatography-atmospheric pressure ionization tandem mass speclrometry. J Chromatogr 777: 61
22. 22. Bryant MS, Liu M, Korfmacher WA, Nardo C, et al (1997) LC-APCI/MS/MS analysis of serum and tumor samples from mice treated with a potent antitumor compound (SCH 59228). Proceedings the 45th ASMS Conference on Mass Spectrometry and Allied Topics, Palm Springs, CA
23. 23. Mallams AK, Njoroge FG, Doll RJ, Snow ME, et al (1997) Antilumor 8-chlorobenzocycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of Ras farnesylation. Bioorg Med Chem 5: 93
24. 24. Dexter DL, Barbosa JA, Calabresi PN (1979) N-dimethylformamide-induced alteration of cell culture characteristics and loss of tumorigenicity in cultured human colon carcinoma cells. Cancer Res 39: 1020
25. 25. Kohl NE, Mosser SD, DeSolms J, Giuliani EA, et al (1993) Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260: 1934
26. 26. James GL, Goldstein JL, Brown MS, Rawson TE, et al (1993) Benzodiazepine peptomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 260: 1937
27. 27. Garcia AM, Rowell C, Ackermann K, Kowalezyk JJ, et al (1993) Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J Biol Chem 268: 18415
28. 28. Vogt A, Qian Y, Blaskovich MA, Fossum RD, et al (1995) A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing. J Biol Chem 270: 660
29. 29. Hunt JT, Lee VG, Leftheris K, Seizinger B, et al (1996) Potent cell active non-thiol tetrapeptide inhibitors of farnesyl-transferase. J Med Chem 39: 353
30. 30. Leftheris K, Kline T, Vite GD, Cho YH, et al (1996) Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity. J Med Chem 39: 224
31. 31. Graham SL, deSolms SJ, Giuliani EA, Kohl NE, et al (1994) Pseudopeplide inhibitors of Ras farnesyl-protein transferase. J Med Chem 37: 725
32. 32. deSolms SJ, Deana AA, Giuliani EA, Graham SL, et al (1995) Pseudodipeptide inhibitor of protein farnesyltransferase. J Med Chem 38: 3967
33. 33. Singh SB, Lingham RB (1996) Farnesyl-protein transferase inhibitors in early development. Exp Opin Invest Drugs 5: 1589
34. 34. Cox AD, Garcia AM, Westwick JK, Kowalezyk JJ, et al (1994) The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated, or myristylated, oncogenic ras signalling and transformation. J Biol Chem 269: 19203
35. 35. Cox AD, Hisaka MM, Buss JE, Der CJ (1992) Specific isoprenoid modification is required for function of normal, but not oncogenic, ras protein. Mol Cell Biol 12: 2606
36. 36. Lebowitz PF, Sakamuro D, Prendergast GC (1997a) Farnesyl transferase inhibitors induce apoptosis of ras-transformed cells denied substratum attachment. Cancer Res 57: 708
37. 37. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA (1997b) Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem 272: 15591
38. 38. Der CJ, Cox AD (1997) Farnesyltransferase inhibitors and cancer treatment: targeting simply ras? Bioehim Biophys Acta Rev Cancer 1333: F5I
39. 39. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, et al (1995) Peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 55: 5302
40. 40. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, et al (1995) Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 55: 5310
41. 41. Kohl NE, Wilson FR, Mosser SD, Giuliani E (1994) Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 91: 9141
42. 42. Kohl NE, Omer CA, Conner MW, Anthony NJ, et al (1995) Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1: 792
43. 43. Sun J, Qian Y, Hamilton AD, Sebti SM (1995) Ras CAAX peptidomimetic FTI 276 selectively blocks tumour growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 55: 4243